ESCLEROSIS MÚLTIPLE
![Foto de ESCLEROSIS MÚLTIPLE](/img/grupo.png)
![Foto de Hospital Ramón y Cajal](/img/noimage_org.png)
Hospital Ramón y Cajal
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (25)
2024
-
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study
Multiple Sclerosis and Related Disorders, Vol. 90
-
Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479] (Autoimmunity Reviews (2023) 22(12), (S1568997223002136), (10.1016/j.autrev.2023.103479))
Autoimmunity Reviews
-
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 95, Núm. 5, pp. 410-418
2023
-
Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach
Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 9, Núm. 2
-
Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
Patient Preference and Adherence, Vol. 17, pp. 1431-1439
-
Laboratory and clinical practices in antinuclear antibody detection and related antigens: recommendations from a Spanish multicentre survey
Immunologic Research, Vol. 71, Núm. 5, pp. 749-759
-
Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel
Autoimmunity Reviews, Vol. 22, Núm. 12
2022
-
Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis
Multiple Sclerosis and Related Disorders, Vol. 68
-
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology
Multiple Sclerosis and Related Disorders, Vol. 63
-
Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis
Human Molecular Genetics, Vol. 31, Núm. 13, pp. 2155-2163
-
Long-term prognosis communication preferences in early-stage relapsing-remitting multiple sclerosis
Multiple Sclerosis and Related Disorders, Vol. 64
-
Measuring productivity loss in early relapsing-remitting multiple sclerosis
Multiple Sclerosis and Related Disorders, Vol. 58
-
Microbial dysbiosis and lack of SCFA production in a Spanish cohort of patients with multiple sclerosis
Frontiers in Immunology, Vol. 13
-
Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis
Journal of Neuroinflammation, Vol. 19, Núm. 1
2021
-
XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (I)
Revista de neurologia, Vol. 72, Núm. 11, pp. 397-406
-
XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (II)
Revista de neurologia, Vol. 72, Núm. 12, pp. 433-442
2020
-
A new risk variant for multiple sclerosis at 11q23.3 locus is associated with expansion of CXCR5+ circulating regulatory T cells
Journal of Clinical Medicine, Vol. 9, Núm. 3
-
Whole-transcriptome analysis in peripheral blood mononuclear cells from patients with lipid-specific oligoclonal igm band characterization reveals two circular RNAs and two linear rnas as biomarkers of highly active disease
Biomedicines, Vol. 8, Núm. 12, pp. 1-16
2019
-
Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis
Clinica Chimica Acta, Vol. 488, pp. 135-142
2015
-
A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis
Human Molecular Genetics, Vol. 24, Núm. 19, pp. 5619-5627